Skip to main content

Non-Antibiotic UTI Prevention

Non-antibiotic strategies can reduce reliance on daily antibiotics in selected patients with recurrent UTI. Choose among them according to menopausal status, trial population, contraindications, and patient preference; the options do not have interchangeable efficacy. The AUA/CUA/SUFU 2025 guideline, WikiGuidelines 2024 consensus, and AGS Beers alternatives document support individualized prevention.[43][2][3] Network meta-analysis combines heterogeneous populations and indirect comparisons; its rankings do not override a well-conducted negative trial or prove interchangeable benefit across products.[4]

This article is the prescribing-detail deep-dive for each modality. For the prevention decision framework, see UTI suppressive & prophylactic therapy; for treatment of active infection, see UTI treatment antibiotics.

Vaginal estrogen​

AUA/CUA/SUFU 2025: recommend vaginal estrogen in eligible peri- and postmenopausal women with rUTI (Moderate / Grade B). The earlier 2022 update is retained as historical context.[1][43]

Mechanism​

Hypoestrogenic genitourinary changes can contribute to rUTI in postmenopausal women. Estrogen deprivation leads to vaginal and urethral atrophy, loss of Lactobacillus colonization, rising vaginal pH, and increased uropathogen colonization — vaginal estrogen reverses all three.[5]

Formulations and prescribing​

Use the vaginal estrogen hub for formulation-specific loading, maintenance and labels. Low-dose vaginal estradiol creams, inserts and the local ring have different regimens; a systemic vaginal ring is not an interchangeable substitute. Prasterone is not estrogen and is not an established rUTI-prevention substitute.

Efficacy​

  • Raz & Stamm 1993 (landmark RCT, intravaginal estriol) — cumulative infection-free proportion dramatically higher vs placebo over 8 months; the trial that established the modality[6]
  • Chen 2021 meta-analysis (5 RCTs, n = 1,936) — vaginal estrogen reduced rUTI with RR 0.42 (95% CI 0.30–0.59); oral/systemic estrogen showed no benefit (RR 1.11; 95% CI 0.92–1.35) and should not be used for UTI prevention[7]
  • Tan-Kim 2023 (retrospective, n = 5,638 women prescribed vaginal estrogen for rUTI) — 51.9% reduction in UTI frequency in the year following prescription (3.9 → 1.8 episodes/year; p < 0.001); this before/after association does not establish the size of a causal treatment effect[8]

Safety​

Local irritation and spotting can occur; absorption depends on product and dose. A history of breast cancer requires individualized counseling and, particularly during aromatase-inhibitor therapy, coordination with oncology. Do not imply that prasterone is automatically safer in this setting. Persistent or recurrent postmenopausal bleeding needs evaluation. Use the estrogen hub for current product-label and endometrial-safety details.

See GSM for the clinical framework and the estrogen hub for July 2026 TAPER application evidence and current product-label counseling.

Methenamine hippurate​

AUA/CUA/SUFU 2025: methenamine hippurate may be offered for prophylaxis in women with rUTI (Conditional Recommendation, Grade C). This recommendation was added in 2025; it was not an endorsement in the 2022 version.[43]

Mechanism: methenamine releases formaldehyde in acidic urine; this pH dependence does not establish a benefit from routinely adding an acidifier.[44]

Urine pH and vitamin C​

  • Do not routinely add vitamin C to methenamine. The AUA 2025 discussion advises against the combination because urinary acidifiers have not reliably lowered urine pH or enhanced methenamine efficacy.[43]
  • ALTAR did not test the added value of acidification. Its non-inferiority result is evidence for methenamine prophylaxis, not proof that supplemental vitamin C helps.[10]
  • The US label advises attention to urinary pH and clinical response, review of alkalinizing foods/medicines, and supplemental acidification only if necessary. It gives no universal numeric urine-pH target. This conditional label language should not become an automatic vitamin-C prescription.[44]
  • Cranberry is not an established replacement acidifier. An older crossover study in catheterized patients found no additional benefit from cranberry added to methenamine/ascorbic acid; its population and methenamine-mandelate formulation differ from ALTAR. See the cranberry section for its separate prevention evidence.[45]

Formaldehyde was long believed to be resistance-proof because it denatures proteins non-specifically. Hodgkinson 2026 analyzed E. coli isolates from the ALTAR trial and identified formaldehyde-detoxification resistance (FDHR) — 5.8% of isolates grew in > 1 mM formaldehyde via non-functional FrmR repressor variants or plasmid-encoded frmA homologues — showing methenamine carries some resistance risk, though clinical significance is undefined.[40]

Dosing​

  • Standard regimen: 1 g PO BID (adults and patients > 12 years). Use after treatment of an active infection; it is not an acute-UTI treatment.[44]
  • Trials studied 6–12 months; reassess benefit, adverse effects, and breakthrough infections rather than assuming indefinite treatment.[10][12]

Efficacy​

  • ALTAR trial (Harding 2022, n = 240, multicenter open-label non-inferiority RCT) — methenamine non-inferior to daily low-dose antibiotics (nitrofurantoin 50–100 mg, trimethoprim 100 mg, or cefalexin 250 mg) at 12 months (1.38 vs 0.89 episodes/person-year; within the 1-episode non-inferiority margin). Antibiotic resistance in perineal E. coli was higher in the antibiotic arm during treatment (72% vs 56%; p = 0.05), though post-treatment multidrug resistance was paradoxically higher in the methenamine arm (20% vs 5%; p = 0.06)[10][11]
  • ImpresU trial (Heltveit-Olsen 2025, 289 recruited / 281 analyzed women ≥ 70 y, triple-blind placebo-controlled phase IV) — 25% reduction in antibiotic-treated UTIs at 6 months (IRR 0.75; 95% CI 0.57–1.0; p = 0.049); rebound increase in UTI rate after discontinuation (IRR 1.7; p < 0.05) — discuss recurrence after stopping and reassess; the trial did not establish indefinite-treatment benefit or safety[12]
  • Lee 2012 Cochrane review (13 studies, n = 2,032) — effective in patients without renal-tract abnormalities (RR 0.24; 95% CI 0.07–0.89) but benefit was not established in those with renal-tract abnormalities or neuropathic bladder (RR 1.54; 95% CI 0.38–6.20)[41]
  • Davidson 2024 systematic review (7 studies) — a review of selected clinical studies; it does not remove population-specific uncertainty[13]

Special populations​

  • Neurogenic bladder / SCI — do not extrapolate ALTAR to neuropathic bladder: that population was excluded. The SINBA placebo-controlled trial in SCI did not show longer time to symptomatic UTI with methenamine. Evaluate the bladder-management program and structural causes of recurrence.[10][46]
  • Renal transplant recipients — a small retrospective series reported fewer UTIs and admissions with methenamine plus vitamin C, but it cannot establish an added benefit from vitamin C or override US-label contraindications. Review renal function and concurrent prophylaxis with the transplant team; do not combine with TMP-SMX.[42][44]

Safety​

  • The US label contraindicates renal insufficiency, severe hepatic insufficiency, and severe dehydration. It supplies no numerical eGFR/CrCl cutoff; a research eligibility cutoff must not be substituted for the label.[44]
  • Do not combine with sulfonamides, including TMP-SMX, because of urinary precipitation with formaldehyde. Check the breakthrough-UTI treatment plan as well as daily prophylaxis.[44]
  • Alkaline urine may impair activity, particularly with urease-producing organisms. Persistent or recurrent Proteus infection warrants reassessment rather than an assertion that methenamine never works against that organism.[44]
  • Label-reported adverse effects include nausea, stomach upset, dysuria, and rash; excessive doses can irritate the bladder and cause hematuria. The branded tablet contains tartrazine. The label advises periodic liver-function tests, particularly with hepatic dysfunction.[44]

Cranberry products​

Mechanism: proanthocyanidins (PAC) — especially A-type PACs — inhibit P-fimbriae-mediated adherence of uropathogenic E. coli to uroepithelial cells. B-type PACs (apple juice, grape juice, chocolate) lack this anti-adhesion property. Mechanistic anti-adhesion findings do not establish a universally superior twice-daily clinical regimen.[30]

Dose — PAC content matters more than form​

  • WikiGuidelines 2024 recommends products containing ≥36 mg PAC per day for women, children, and people susceptible to UTI after interventions.[2]
  • Juice, capsules, and whole-fruit powder have all been studied; standardized capsule with declared PAC content is the most reproducible form. Cranberry products are regulated as dietary supplements, not drugs — PAC content and quality vary considerably between brands.[30]
  • Whole-fruit powder mass is not interchangeable with PAC content; check the studied product and declared assay/content
  • Trial PAC doses span 18–72 mg/day; the Cochrane review found no clear dose-response relationship across low, moderate (40–80 mg/day), and high (>80 mg/day) PAC doses[30]

Efficacy​

The 2023 Cochrane review (Williams, 50 RCTs, 8,857 participants) is the comprehensive synthesis, and the benefit is population-specific:[30]

PopulationRR (95% CI)Certainty
Women with recurrent UTI0.74 (0.55–0.99)Moderate
Children0.46 (0.32–0.68)Moderate
Susceptible after an intervention0.47 (0.37–0.61)Low
Elderly institutionalized0.93 (0.67–1.30)Moderate — benefit not demonstrated
Pregnant women1.06 (0.75–1.50)Moderate — benefit not demonstrated
Neurogenic bladder0.97 (0.78–1.19)Low — benefit not demonstrated
  • Analyzed specifically as tablets / powder, cranberry reduced UTI risk in women with rUTI by ~ 55% (RR 0.45; 95% CI 0.28–0.72; 3 studies, n = 333)[30]
  • Stonehouse 2025 (multicenter, double-blind, placebo-controlled, n = 150 women with rUTI) — whole cranberry fruit powder 500 mg/day reduced culture-confirmed UTI by 52% (aRR 0.48; 95% CI 0.26–0.87; p = 0.01), delayed time to first UTI (HR 0.36; p = 0.01), and reduced total episodes (IRR 0.41; p = 0.01)[14]
  • Versus antibiotics, the pooled comparison was imprecise (RR 1.03; 95% CI 0.80–1.33), not proof of equivalence; versus probiotics it was superior (RR 0.39; 95% CI 0.27–0.56)[30]
  • Xia 2021 meta-analysis with trial sequential analysis (23 trials, n = 3,979) reported benefit in pooled susceptible populations; newer population-specific Cochrane estimates are more useful for counseling (RR 0.70; 95% CI 0.59–0.83)[31]
  • Beerepoot 2013 meta-analysis — pooled RR 0.53 (95% CI 0.33–0.83)[9]
  • The Juthani-Mehta 2016 nursing-home RCT (72 mg PAC capsule) found no reduction in bacteriuria-plus-pyuria — consistent with the Cochrane elderly-institutionalized null[32]

Prevention only — not treatment​

A separate Cochrane review found no reliable evidence that cranberry products treat an active UTI. Cranberry is a preventive strategy only.[33]

Safety​

GI adverse effects are possible (Cochrane RR 1.33; 95% CI 1.00–1.77). Supplement composition varies. Review cranberry use with the anticoagulation team when a patient takes warfarin, especially after changing intake; uncertain interaction and stone data do not support a guarantee of safety at a universal “standard” dose.[30][34]

D-mannose​

Mechanism: D-mannose is a monosaccharide (a C-2 epimer of glucose) found naturally in cranberries, grapes, and apples. After oral absorption it is excreted largely unchanged into urine, where it binds the FimH adhesin on the tip of type 1 pili of uropathogenic E. coli, competitively blocking adherence to urothelial mannose receptors so bacteria are voided rather than colonizing. The effect is FimH-specific — primarily relevant to E. coli. Urinary half-life is ~ 4 hours, the rationale for multiple daily doses. Pharmacologically attractive; clinically underwhelming in recent rigorous data.[35]

AUA/CUA/SUFU 2025: explain that D-mannose monotherapy may not prevent rUTI (Moderate Recommendation, Grade B). A specialist referral alone is not evidence of an effective treatment subgroup.[43]

Evidence — conflicting​

The evidence splits sharply between earlier open-label trials and the larger blinded RCT:

  • Kranjčec 2014 — open-label 3-arm RCT (n = 308) in women with acute cystitis and rUTI history: 6-month recurrence 14.6% (D-mannose 2 g/day) vs 20.4% (nitrofurantoin) vs 60% (no treatment)[36]
  • Porru 2014 — randomized crossover (n = 60): mean time to recurrence 200 days (D-mannose) vs 52.7 days (co-trimoxazole)[37]
  • Lenger 2020 meta-analysis — pooled RR 0.23 (95% CI 0.14–0.37) vs placebo, driven by these open-label studies[38]
  • Han 2025 network meta-analysis — largest effect size of any non-antibiotic intervention (RR 0.34; 95% CI 0.21–0.56), again weighted by smaller / older studies[4]
  • MERIT RCT (Hayward 2024, JAMA Intern Med) — double-blind, placebo-controlled, n = 598 women with rUTI recruited from UK primary care: no significant benefit — 51.0% vs 55.7% with a medically attended UTI over 6 months (primary-outcome risk difference −5 percentage points; 95% CI −13 to 3), with no difference in symptom burden, time to next UTI, antibiotic use, or serious adverse events, and consistency across pre-/postmenopausal subgroups[16]
  • WikiGuidelines 2024 concludes insufficient evidence to recommend for or against[2]

Reconciling the discrepancy: the favorable trials were open-label (vulnerable to expectation effects on symptom reporting and healthcare-seeking), enrolled women at the point of active cystitis, and recruited from specialist urology clinics; MERIT was blinded, enrolled women between infections, and recruited from primary care. A 2026 review proposed setting-specific use, but this interpretation does not establish a validated responder subgroup and should not override counseling about the negative blinded evidence.[39][43]

Dosing (when used despite the equivocal evidence)​

No standardized dose; trials span 200 mg–3 g/day. Typical regimen 2 g PO once daily or 1 g BID dissolved in water (the 2 g/day dose used in both Kranjčec and MERIT). Routine prophylactic use is not supported by the largest blinded trial; no prospectively validated responder subgroup establishes a specialist-only exception.[16][43]

Safety​

Generally well tolerated; diarrhea is the most common adverse event, with rare vaginal burning, and MERIT found no excess serious adverse events.[16][35] Despite being a sugar, D-mannose has minimal effect on glucose metabolism at standard doses (most is excreted unmetabolized), though caution is reasonable in diabetic patients given that it does stimulate insulin secretion.[35]

Prevention only — not treatment​

The Cochrane review found no reliable evidence that D-mannose treats an active UTI; its anti-adhesion mechanism suits prevention, not established infection.[35]

Hydration (≥1.5 L/day increase)​

Hooton 2018 (JAMA Intern Med, RCT, n = 140 premenopausal women with rUTI and low baseline fluid intake) — adding 1.5 L of water daily cut recurrences by ~50% over 12 months (1.7 vs 3.2 episodes; p < 0.001) and reduced antimicrobial regimen use comparably.[17]

  • Low-risk, zero-resistance-pressure intervention
  • Confirmatory studies in postmenopausal women and patients with neurogenic bladder are awaited, so offer to appropriate low-volume drinkers rather than assuming the same effect in every rUTI population; respect fluid restrictions

Probiotics​

Heterogeneous evidence across strains, routes, and populations. The Han 2025 network meta-analysis found RR 0.69 (95% CI 0.50–0.94) with the strongest signal in pediatric subgroups (RR 0.50; 95% CI 0.28–0.89).[4] WikiGuidelines 2024 found inconclusive evidence and makes no formal recommendation.[2]

  • Most studied strains: vaginal Lactobacillus crispatus CTV-05 (Lactin-V), L. rhamnosus GR-1, L. reuteri RC-14
  • Route matters: vaginal delivery plausibly more directly relevant than oral for urinary colonization
  • Do not assume any commercial probiotic reproduces a trial strain or establishes benefit as an estrogen adjunct

Immunoprophylaxis​

These products are not FDA-approved in the US. EAU 2026 weakly recommends immunomodulatory prophylaxis only in a well-regulated clinical trial; older regional recommendations have a different evidence date and context.[47]

OM-89 (Uro-Vaxom) — oral E. coli lysate​

  • Bauer 2005 RCT (n = 453, multicenter double-blind) — 34% reduction in UTI rate (0.84 vs 1.28 episodes; p < 0.001) with favorable safety[18]
  • Beerepoot 2013 meta-analysis — pooled RR 0.61 (95% CI 0.48–0.78)[9]
  • Volontè 2025 systematic review — describes favorable studies; heterogeneous results and the current EAU trial-only recommendation limit generalization[19]
  • Older Latin American consensus — Grade A recommendation (regional/historical, not a current universal endorsement)[20]
  • Regimen: 6 mg PO once daily for 3 months (re-courses available)

MV140 (Uromune) — sublingual polybacterial spray​

  • Whole-cell heat-inactivated E. coli, K. pneumoniae, P. vulgaris, E. faecalis
  • Lorenzo-Gómez 2021 frail-elderly cohort reported fewer episodes after treatment, but uncontrolled before/after changes cannot establish efficacy[21]
  • A completed 240-woman, industry-funded randomized trial (2022) found a median of 0 UTIs with either three or six months of MV140 versus 3 with placebo during the nine-month efficacy period. UTI-free proportions were 56%, 58% and 25%, respectively. This is encouraging, but of limited size/duration and not proof for complex reconstructive populations.[48]

Urovac — vaginal mucosal vaccine​

  • Modest reduction (RR 0.75; 95% CI 0.63–0.89); booster immunization extends time to reinfection[22]

Aziminia 2019 systematic review — 10 RCTs, n = 1,537​

Pooled RR 0.74 (95% CI 0.67–0.81) for vaccines vs placebo; evidence quality low with substantial heterogeneity.[22]

Vitamin D​

Mechanism: vitamin D induces cathelicidin (LL-37), a cationic antimicrobial peptide expressed by bladder urothelium and neutrophils.[23]

Evidence​

  • Jorde 2016 (RCT, n = 511 prediabetic subjects) — vitamin D3 20,000 IU/week for 5 years significantly reduced UTI reports vs placebo (18 vs 34 subjects; p < 0.05)[24]
  • D-Health Trial (Pham 2022, n = 21,315 older Australian adults) — the overall antibiotic-prescription endpoint was not significantly reduced (IRR 0.98; 95% CI 0.95–1.01); a favorable subgroup used predicted low vitamin D status. This is not direct proof of rUTI prevention[25]
  • Han 2025 network meta-analysis — RR 0.46 (95% CI 0.27–0.81) in the long follow-up subgroup (≥1 year)[4]

Not yet in major rUTI guideline recommendations. Correct established deficiency for its usual indications; do not prescribe high-dose vitamin D solely as proven rUTI prevention.

Intravesical GAG replenishment (HA ± CS)​

Intravesical hyaluronic acid ± chondroitin sulfate is intended to restore the protective GAG layer of the bladder urothelium, reducing bacterial adherence and neurogenic inflammation. Primarily European practice; primarily deployed in refractory rUTI when non-antibiotic and antibiotic strategies have failed.

Evidence​

  • Damiano 2011 placebo-controlled RCT (n = 57) — HA-CS instillation reduced UTI rate by 86.6% vs 9.6% placebo (p = 0.0002) and extended time to first recurrence (185 vs 53 days; p < 0.05)[26]
  • Corona 2025 meta-analysis — HA-CS reduced infection rates vs placebo or standard care (OR 0.42; 95% CI 0.25–0.49; p < 0.001)[27]
  • The 2026 Kwon review found the pooled HA–CS effect imprecise (RR 0.41; 95% CI 0.04–4.77), illustrating uncertainty across study sets; do not interpret all instillation products as equally established.[29]
  • Goddard 2018 systematic review + meta-analysis — HA ± CS decreased UTI rate per patient-year (pooled MD −2.56; 95% CI −3.86 to −1.26; p < 0.001)[28]

Practical notes​

  • Typical regimen: weekly instillation × 4, then monthly maintenance; protocol varies by product
  • Commercial products include iAluril (HA-CS), Cystistat (HA), Uracyst (CS)
  • Cross-covered in detail in Intravesical IC/BPS agents — same molecules used for bladder pain syndrome

Intravesical aminoglycoside instillation​

Intravesical gentamicin or amikacin is antibiotic treatment delivered locally, included here as an alternative to systemic prophylaxis. It is an off-label, specialist option for selected refractory cases, particularly patients already catheterizing; routine instillation into every long-term catheter is not established.

  • Kwon 2026 systematic review + meta-analysis — intravesical aminoglycoside instillation produced the most marked reduction in recurrence among intravesical therapies (pooled IRR 0.23; 95% CI 0.15–0.37), in a mixed randomized/observational evidence base. The review reported low measured systemic exposure and few adverse events, but called for larger standardized RCTs[29]

Practical notes​

Use a pharmacy-verified local regimen with explicit dose, dilution, dwell time, catheter technique and reassessment. Published regimens differ; a single “typical” gentamicin or amikacin recipe is not validated across patients. The AUA NLUTD guideline allows bladder instillation for CIC users with recurrent UTI as Expert Opinion.[49]

Systemic absorption is usually low but not guaranteed absent: a long-term cohort found one detectable level during macroscopic hematuria after bladder biopsy. Consider mucosal injury, renal function, exposure and local monitoring policy. Obtain cultures for symptomatic breakthrough episodes and use a defined resistance-surveillance plan without treating asymptomatic bacteriuria automatically.[50]

Behavioral modifications​

Review spermicide exposure and baseline water intake. Address clinically relevant incomplete emptying or bowel dysfunction. EAU discusses several low-risk habits despite limited evidence, whereas AUA notes that wiping direction and pre/post-coital voiding have not been shown to prevent rUTI. Do not present hygiene rituals as proven therapy or imply that recurrence reflects poor hygiene.[15][17][43][47]

Evidence Summary​

InterventionStrength of evidenceEffect sizeGuideline status
Vaginal estrogenModerate (meta-analysis of RCTs)RR 0.42–0.58AUA Moderate / Grade B[1][7]
Methenamine hippurateNon-inferiority RCT + placebo-controlled phase IV RCTALTAR met its prespecified margin; ImpresU studied older womenAUA 2025 Conditional / Grade C[10][12][43]
Cranberry (≥36 mg PAC)Moderate (multiple RCTs)Cochrane rUTI subgroup RR 0.74AUA 2025 Moderate / Grade B; product variability[30][43]
Hydration +1.5 L/dayLow (single RCT)~50% reductionWikiGuidelines recommended[17]
D-mannoseConflicting (network meta positive; largest RCT negative)RR 0.34 vs nullWikiGuidelines insufficient evidence[4][16]
ProbioticsLow / inconclusiveRR 0.69WikiGuidelines inconclusive[4]
OM-89 (Uro-Vaxom)Moderate (multiple RCTs)RR 0.61Latin American Grade A; not FDA-approved[9][18][19]
MV140 (Uromune)One placebo-controlled RCT plus cohorts56–58% versus 25% UTI-free in the RCTEAU trial-only; not FDA-approved[47][48]
Vitamin DLow (limited RCTs)RR 0.46 in long-follow-up subgroupNot in major guidelines[4][24]
Intravesical HA ± CSLow–moderate (small RCTs, meta-analysis)OR 0.42; MD −2.56/pyRefractory-rUTI option (mainly European)[27][28]
Intravesical aminoglycosidesLow–moderate (meta-analysis)IRR 0.23Selected refractory cases; heterogeneous protocols[29]
Behavioral counselingIntervention-specificHydration evidence applies to low-volume drinkersHygiene rituals are not established prevention

Clinical Positioning​

  • Vaginal estrogen is first-line in postmenopausal women with rUTI regardless of whether GSM symptoms are the presenting complaint — the 2023 Tan-Kim real-world data (51.9% reduction, n = 5,638) and Chen meta-analysis (RR 0.42) are the anchor evidence.[7][8]
  • Systemic estrogen has no role in UTI prevention — use vaginal routes only.[7]
  • Discuss methenamine as an alternative to daily antibiotic prophylaxis for eligible women with rUTI. ALTAR met a one-UTI/person-year non-inferiority margin; this does not mean identical recurrence rates or freedom from resistance. Do not add routine vitamin C.[10][11][43]
  • Offer cranberry as an option, explaining uncertain optimal PAC dose and product variability rather than promising benefit above a threshold.[2][14]
  • D-mannose is no longer routinely recommended. The MERIT primary-care RCT is the largest, most rigorous, and negative.[16]
  • Consider increased water for low-volume drinkers; Hooton enrolled premenopausal women drinking less than 1.5 L/day. Do not extrapolate a fixed extra volume to everyone.[17]
  • Immunoprophylaxis requires jurisdiction-specific review; EAU 2026 recommends use in a regulated trial, and these products are not FDA-approved in the US.[19][20][21]
  • Correct vitamin D deficiency for standard indications, without claiming proven UTI prevention.[4][23][24]
  • Intravesical therapy (HA/CS, aminoglycoside) is for refractory rUTI — escalate to this tier when oral non-antibiotics and appropriate antibiotic strategies have failed. The 2026 Kwon review supports further study of aminoglycosides (IRR 0.23); different pooled measures and study populations do not establish superiority in a head-to-head comparison.[29]
  • Discuss useful behavioral measures without hygiene blame. Spermicide avoidance and hydration assessment have a different evidence basis from wiping direction or postcoital voiding.

See Also​

References​

1. Anger JT, Bixler BR, Holmes RS, et al. "Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline." J Urol. 2022;208(3):536–541. doi:10.1097/JU.0000000000002860

2. Nelson Z, Aslan AT, Beahm NP, et al. "Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement." JAMA Netw Open. 2024;7(11):e2444495. doi:10.1001/jamanetworkopen.2024.44495

3. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

4. Han Z, Yi X, Li J, Liao D, Ai J. "Nonantibiotic prophylaxis for urinary tract infections: a network meta-analysis of randomized controlled trials." Infection. 2025;53(2):535–546. doi:10.1007/s15010-024-02357-z

5. Buck ES, Lukas VA, Rubin RS. "Effective prevention of recurrent UTIs with vaginal estrogen: pearls for a urological approach to genitourinary syndrome of menopause." Urology. 2021;151:31–36. doi:10.1016/j.urology.2020.05.058

6. Raz R, Stamm WE. "A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections." N Engl J Med. 1993;329(11):753–756. doi:10.1056/NEJM199309093291102

7. Chen YY, Su TH, Lau HH. "Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials." Int Urogynecol J. 2021;32(1):17–25. doi:10.1007/s00192-020-04397-z

8. Tan-Kim J, Shah NM, Do D, Menefee SA. "Efficacy of vaginal estrogen for recurrent urinary tract infection prevention in hypoestrogenic women." Am J Obstet Gynecol. 2023;229(2):143.e1–143.e9. doi:10.1016/j.ajog.2023.05.002

9. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. "Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials." J Urol. 2013;190(6):1981–1989. doi:10.1016/j.juro.2013.04.142

10. Harding C, Mossop H, Homer T, et al. "Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open-label, randomised, non-inferiority trial (ALTAR)." BMJ. 2022;376:e068229. doi:10.1136/bmj-2021-0068229

11. Harding C, Chadwick T, Homer T, et al. "Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT." Health Technol Assess. 2022;26(23):1–172. doi:10.3310/QOIZ6538

12. Heltveit-Olsen SR, Arnljots ES, Sundvall PD, et al. "Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women — a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU)." Clin Microbiol Infect. 2025. doi:10.1016/j.cmi.2025.07.006

13. Davidson SM, Brown JN, Nance CB, Townsend ML. "Use of methenamine for urinary tract infection prophylaxis: systematic review of recent evidence." Int Urogynecol J. 2024;35(3):483–489. doi:10.1007/s00192-024-05726-2

14. Stonehouse W, Benassi-Evans B, Bednarz J, Vincent AD. "Whole cranberry fruit powder supplement reduces the incidence of culture-confirmed urinary tract infections in females with a history of recurrent urinary tract infection: a 6-month multicenter, randomized, double-blind, placebo-controlled trial." Am J Clin Nutr. 2025;121(4):932–941. doi:10.1016/j.ajcnut.2025.01.022

15. Schmiemann G, Kranz J, Mandraka F, et al. "The diagnosis, treatment, and prevention of recurrent urinary tract infection." Dtsch Arztebl Int. 2024;121(11):373–382. doi:10.3238/arztebl.m2024.0068

16. Hayward G, Mort S, Hay AD, et al. "D-mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial (MERIT)." JAMA Intern Med. 2024;184(6):619–628. doi:10.1001/jamainternmed.2024.0264

17. Hooton TM, Vecchio M, Iroz A, et al. "Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial." JAMA Intern Med. 2018;178(11):1509–1515. doi:10.1001/jamainternmed.2018.4204

18. Bauer HW, Alloussi S, Egger G, et al. "A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections." Eur Urol. 2005;47(4):542–548. doi:10.1016/j.eururo.2004.12.009

19. Volontè S, De Vicari D, Cola A, Barba M, Frigerio M. "Efficacy and safety of Uro-Vaxom in urinary tract infection prevention: a systematic literature review." J Clin Med. 2025;14(11):3836. doi:10.3390/jcm14113836

20. Haddad JM, Ubertazzi E, Cabrera OS, et al. "Latin American consensus on uncomplicated recurrent urinary tract infection — 2018." Int Urogynecol J. 2020;31(1):35–44. doi:10.1007/s00192-019-04079-5

21. Lorenzo-Gómez MF, Padilla-Fernández B, Flores-Fraile J, et al. "Impact of whole-cell bacterial immunoprophylaxis in the management of recurrent urinary tract infections in the frail elderly." Vaccine. 2021;39(42):6308–6314. doi:10.1016/j.vaccine.2021.08.093

22. Aziminia N, Hadjipavlou M, Philippou Y, et al. "Vaccines for the prevention of recurrent urinary tract infections: a systematic review." BJU Int. 2019;123(5):753–768. doi:10.1111/bju.14606

23. Hertting O, Holm Å, Lüthje P, et al. "Vitamin D induction of the human antimicrobial peptide cathelicidin in the urinary bladder." PLoS One. 2010;5(12):e15580. doi:10.1371/journal.pone.0015580

24. Jorde R, Sollid ST, Svartberg J, et al. "Prevention of urinary tract infections with vitamin D supplementation 20,000 IU per week for five years. Results from an RCT including 511 subjects." Infect Dis (Lond). 2016;48(11–12):823–828. doi:10.1080/23744235.2016.1201853

25. Pham H, Waterhouse M, Baxter C, et al. "Vitamin D supplementation and antibiotic use in older Australian adults: an analysis of data from the D-Health Trial." J Infect Dis. 2022;226(6):949–957. doi:10.1093/infdis/jiac279

26. Damiano R, Quarto G, Bava I, et al. "Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial." Eur Urol. 2011;59(4):645–651. doi:10.1016/j.eururo.2010.12.039

27. Corona G, Capogrosso P, Baldini S, et al. "Hyaluronic acid and chondroitin sulphate instillation in chronic bladder diseases: a meta-analysis." BJU Int. 2025. doi:10.1111/bju.70016

28. Goddard JC, Janssen DAW. "Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis." Int Urogynecol J. 2018;29(7):933–942. doi:10.1007/s00192-017-3508-z

29. Kwon M, Ahmad A, Lott N, Blatt A. "Intravesical therapy for recurrent urinary tract infection: a systematic review and meta-analysis." BJU Int. 2026. doi:10.1111/bju.70252

30. Williams G, Stothart CI, Hahn D, et al. "Cranberries for preventing urinary tract infections." Cochrane Database Syst Rev. 2023;11:CD001321. doi:10.1002/14651858.CD001321.pub7

31. Xia JY, Yang C, Xu DF, et al. "Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: a systematic review and meta-analysis with trial sequential analysis." PLoS One. 2021;16(9):e0256992. doi:10.1371/journal.pone.0256992

32. Juthani-Mehta M, Van Ness PH, Bianco L, et al. "Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: a randomized clinical trial." JAMA. 2016;316(18):1879–1887. doi:10.1001/jama.2016.16141

33. Jepson RG, Mihaljevic L, Craig JC. "Cranberries for treating urinary tract infections." Cochrane Database Syst Rev. 2023;12:CD001322. doi:10.1002/14651858.CD001322.pub2

34. Madden E, McLachlan C, Oketch-Rabah H, Calderón AI. "Safety of cranberry: evaluation of evidence of kidney stone formation and botanical drug-interactions." Planta Med. 2021;87(10-11):803–817. doi:10.1055/a-1497-6241

35. Cooper TE, Teng C, Howell M, et al. "D-mannose for preventing and treating urinary tract infections." Cochrane Database Syst Rev. 2022;8:CD013608. doi:10.1002/14651858.CD013608.pub2

36. Kranjčec B, Papeš D, Altarac S. "D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial." World J Urol. 2014;32(1):79–84. doi:10.1007/s00345-013-1091-6

37. Porru D, Parmigiani A, Tinelli C, et al. "Oral D-mannose in recurrent urinary tract infections in women: a pilot study." J Clin Urol. 2014;7(3):208–213. doi:10.1177/2051415813518332

38. Lenger SM, Bradley MS, Thomas DA, et al. "D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis." Am J Obstet Gynecol. 2020;223(2):265.e1–265.e13. doi:10.1016/j.ajog.2020.05.048

39. Munir A, Tarannum T, Saad N, Abdaal M. "Effectiveness of non-antibiotic therapies in the management of recurrent urinary tract infections in women: a systematic review." Int Urogynecol J. 2026. doi:10.1007/s00192-026-06654-z

40. Hodgkinson NC, Al-Rubaye T, Reed TCP, et al. "Implications for methenamine hippurate use in recurrent urinary tract infection management: formaldehyde resistance and altered urinary composition." PLoS Pathog. 2026;22(3):e1014081. doi:10.1371/journal.ppat.1014081

41. Lee BS, Bhuta T, Simpson JM, Craig JC. "Methenamine hippurate for preventing urinary tract infections." Cochrane Database Syst Rev. 2012;10:CD003265. doi:10.1002/14651858.CD003265.pub3

42. Hollyer I, Varias F, Ho B, Ison MG. "Safety and efficacy of methenamine hippurate for the prevention of recurrent urinary tract infections in adult renal transplant recipients: a single center, retrospective study." Transpl Infect Dis. 2019;21(3):e13063. doi:10.1111/tid.13063

43. Ackerman AL, Bradley M, D'Anci KE, et al. "Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025)." J Urol. 2025. doi:10.1097/JU.0000000000004723. Full guideline, statements 12–17.

44. Validus Pharmaceuticals LLC. HIPREX (methenamine hippurate tablets USP): US prescribing information. July 2021; DailyMed record revised February 2022. Prescribing information. Accessed September 11, 2026.

45. Nahata MC, Cummins BA, McLeod DC, Schondelmeyer SW, Butler R. "Effect of urinary acidifiers on formaldehyde concentration and efficacy with methenamine therapy." Eur J Clin Pharmacol. 1982;22:281–284. doi:10.1007/BF00545228.

46. Lee BB, Haran MJ, Hunt LM, et al. "Spinal-injured neuropathic bladder antisepsis (SINBA) trial." Spinal Cord. 2007;45:542–550. doi:10.1038/sj.sc.3101974.

47. European Association of Urology. EAU Guidelines on Urological Infections. 2026. Full guideline.

48. Lorenzo-Gómez MF, Foley S, Nickel JC, et al. Sublingual MV140 for prevention of recurrent urinary tract infections. NEJM Evid. 2022. doi:10.1056/EVIDoa2100018.

49. AUA/SUFU. Adult neurogenic lower urinary tract dysfunction: treatment and follow-up. 2021. Statements 37–39. doi:10.1097/JU.0000000000002239.

50. Bilsen MP, van Uhm JIM, Stalenhoef JE, et al. Intravesical aminoglycoside instillations as prophylaxis for recurrent urinary tract infection: patient satisfaction, long-term safety and efficacy. JAC Antimicrob Resist. 2023;5:dlad040. doi:10.1093/jacamr/dlad040.